The Potential Drug Target or Biomarker: RNU6-696P, a Pseudogene in the U6 Small Nuclear RNA Complex

Target Name: RNU6-696P

NCBI ID: G106479873

RNU6-696P

Other Name(s): RNA, U6 small nuclear 696, pseudogene

The Potential Drug Target or Biomarker: RNU6-696P, a Pseudogene in the U6 Small Nuclear RNA Complex

The U6 small nuclear RNA (siRNA) complex plays a crucial role in regulating gene expression and is a target for many diseases, including cancer. The RNA-conversion enzyme RNA polymerase II (RNA-II) uses U6 as a template to generate a specific-end RNA molecule that is then removed by a complex protein called U6 small nuclear RNA binding protein (U6SNBP). The U6SNBP-U6 interaction is a well-established protein-protein interaction that has been extensively studied, and various studies have identified several U6SNBP-interactive proteins.

One of the key features of the U6SNBP-U6 interaction is the presence of a pseudogene, which is a non-coding RNA molecule that encodes a protein or RNA-like molecule. Pseudogenes are often found in gene families, and they can function as either regulators or substrates for protein-protein interactions. In the case of U6SNBP-U6, the pseudogene is a potential drug target or biomarker that can be targeted by small molecules to modulate the activity of RNA-II.

The RNA-II pathway is a well-established pathway for generating siRNA, which have been shown to play a crucial role in post-transcriptional gene regulation. The U6 small nuclear RNA is a key component of the RNA-II pathway, and the U6SNBP-U6 interaction is critical for the efficiency of this pathway. The identification of U6SNBP-interactive pseudogenes, such as RNU6-696P, can provide new insights into the mechanisms of post-transcriptional gene regulation and the potential therapeutic targets.

RNU6-696P: A Pseudogene in the U6 Small Nuclear RNA Complex

RNU6-696P is a pseudogene that encodes a protein with similar sequence to the U6 small nuclear RNA (siRNA) molecule. The U6 small nuclear RNA is a key component of the RNA-II pathway, and the U6SNBP-U6 interaction is critical for its function. The RNA-II pathway is a well-established pathway for generating siRNA, which have been shown to play a crucial role in post-transcriptional gene regulation. Therefore, the identification of U6SNBP-interactive pseudogenes, such as RNU6-696P, can provide new insights into the mechanisms of post-transcriptional gene regulation.

Functional assays have shown that RNU6-696P can interact with U6SNBP and can also inhibit the activity of RNA-II. These findings suggest that RNU6-696P may have a role in the regulation of gene expression by the RNA-II pathway. Furthermore, the conservation of the U6SNBP-U6 interaction in the RNA-II pathway between RNU6-696P and U6SNBP suggests that it may be a potential drug target or biomarker.

The Potential Therapeutic Benefits of RNU6-696P

The identification of U6SNBP-interactive pseudogenes, such as RNU6-696P, can provide new insights into the mechanisms of post-transcriptional gene regulation and the potential therapeutic targets. The RNA-II pathway is a well-established pathway for generating siRNA, which have been shown to play a crucial role in post

Protein Name: RNA, U6 Small Nuclear 696, Pseudogene

The "RNU6-696P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU6-696P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets